How relevant are in vivo and in vitro studies for clinical sepsis? A mathematical model of LPS signaling based on endotoxin tolerance

Chirurgia (Romania)

Volumn 104, Issue 2, 2009, Pages 195-201

  Vasilescu, C ^a   Olteanu, M ^b   Flondor, P ^b  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b UNIVERSITY POLITEHNICA OF BUCHAREST   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENDOTOXIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MATHEMATICAL COMPUTING; SEPSIS; THEORETICAL MODEL;

BIOLOGICAL MARKERS; ENDOTOXINS; HUMANS; IMMUNE TOLERANCE; LIPOPOLYSACCHARIDES; MATHEMATICAL COMPUTING; MODELS, THEORETICAL; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904801551     PISSN: 12219118     EISSN: 1842368X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Cross, A. S. - Endotoxin tolerance-current concepts in historical perspective. J. Endotoxin. Res., 2002, 8:83.
2. Beeson, P. B. - Tolerance to bacterial pyrogens. I. Factors influencing its development. J. Exp. Med., 1947, 86:29.
3. Cavaillon, J. M., Adib-Conquy, M. - Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit. Care, 2006, 10:233.
4. Munoz, C., Carlet, J., Fitting, C., Misset, B., Bleriot, J. P., Cavaillon, J. M. - Dysregulation of in vitro cytokine production by monocytes during sepsis, J. Clin. Invest., 1991, 88:1747.
5. West, M. A., Heagy, W. - Endotoxin tolerance: A review, Crit. Care Med., 2002, 30:S64.
6. Dauphinee, S. M., Karsan, A. - Lipopolysaccharide signaling in endothelial cells, Lab. Invest., 2006, 86:9.
7. Triantafilou, M., Triantafilou, K. - The dynamics of LPS recognition: complex orchestration of multiple receptors, J. Endotoxin. Res., 2005, 11:5.
8. Selvarajoo, K. - Discovering differential activation machinery of the Toll-like receptor 4 signaling pathways in MyD88 knockouts, FEBS Lett., 2006, 580:1457.
9. Amura, C. R., Silverstein, R., Morrison, D. C. - Mechanisms involved in the pathogenesis of sepsis are not necessarily reflected by in vitro cell activation studies, Infect. Immun., 1998, 66:5372.
10. Kumar, R., Clermont, G., Vodovotz, Y., Chow, C. C. - The dynamics of acute inflammation, J. Theor. Biol., 2004, 230:145.
11. Day, J., Rubin, J., Vodovotz, Y., Chow, C. C., Reynolds, A., Clermont, G. - A reduced mathematical model of the acute inflammatory response II. Capturing scenarios of repeated endotoxin administration, J. Theor. Biol., 2006, 242:237.
12. Vodovotz, Y. - Deciphering the complexity of acute inflammation using mathematical models, Immunol. Res., 2006, 36:237.
13. Chan, C. C., Stark, J., George, A. J. - Analysis of cytokine dynamics in corneal allograft rejection, Proc. Biol. Sci., 1999, 266:2217.
14. Smith, K. D., Thorsson, V. - Exploring Toll-like receptor regulation of innate immunity with the tools of systems biology, Current Genomics, 2004, 5:1.
15. Takezako, N., Hayakawa, M., Hayakawa, H., Aoki, S., Yanagisawa, K., Endo, H., Tominaga, S. - ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells, Biochem. Biophys. Res. Commun., 2006, 341:425.
16. Brint, E. K., Xu, D., Liu, H., Dunne, A., McKenzie, A. N., O'Neill, L. A., Liew, F. Y. - ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance, Nat. Immunol., 2004, 5:373.
17. Schroder, M., Meisel, C., Buhl, K., Profanter, N., Sievert, N., Volk, H. D., Grutz, G. - Different modes of IL-10 and TGF-beta to inhibit cytokine-dependent IFN-gamma production: consequences for reversal of lipopolysaccharide desensitization, J. Immunol., 2003, 170:5260.
18. Fan, H., Cook, J. A. - Molecular mechanisms of endotoxin tolerance. J. Endotoxin. Res., 2004, 10:71.
19. Amiot, F., Fitting, C., Tracey, K. J., Cavaillon, J. M., Dautry, F. - Lipopolysaccharide-induced cytokine cascade and lethality in LT alpha/TNF alpha-deficient mice, Mol. Med., 1997, 3:864.
20. Grutz, G. - New insights into the molecular mechanism of interleukin-10-mediated immunosuppression, J. Leukoc. Biol., 2005, 77:3.
21. Driessler, F., Venstrom, K., Sabat, R., Asadullah, K., Schottelius, A. J. - Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50, Clin. Exp. Immunol., 2004, 135:64.
22. Behre, G., Schedel, I., Nentwig, B., Wormann, B., Essink, M., Hiddemann, W. - Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins, Antimicrob. Agents Chemother., 1992, 36:2139.
23. Bone, R. C. - The pathogenesis of sepsis, Ann. Intern. Med., 1991, 115:457.
24. Michie, H. R., Spriggs, D. R., Manogue, K. R., Sherman, M. L., Revhaug, A., O'Dwyer, S. T., Arthur, K., Dinarello, C. A., Cerami, A., Wolff, S. M. - Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery, 1988, 104:280.
25. Bozza, F. A., Bozza, P. T., Castro Faria Neto, H. C. - Beyond sepsis pathophysiology with cytokines: what is their value as biomarkers for disease severity?, Mem. Inst. Oswaldo Cruz, 2005, 100(Suppl 1):217.
26. Pinsky, M. R., Vincent, J. L., Deviere, J., Alegre, M., Kahn, R. J., Dupont, E. - Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest, 1993, 103:565.
27. Martins, G. A., Da Gloria Da Costa Carvalho, Rocha, G. C. - Sepsis: a follow-up of cytokine production in different phases of septic patients, Int. J. Mol. Med., 2003 11:585.
28. Cavaillon, J. M., Adrie, C., Fitting, C., Adib-Conquy, M. - Reprogramming of circulatory cells in sepsis and SIRS, J Endotoxin. Res., 2005, 11:311.
29. Copeland, S., Warren, H. S., Lowry, S. F., Calvano, S. E., Remick, D. - Acute inflammatory response to endotoxin in mice and humans, Clin. Diagn. Lab. Immunol., 2005, 12:60.
30. Vasilescu, C., Berger, D., Buttenschon, K., Seidelmann, M., Beger, H. G. - Endotoxin-induced release of interleukin 6 and interleukin 1 beta in human blood is independent of tumor necrosis factor alpha, Eur. Surg. Res., 1996, 28:55.